CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
XueZhiKang +1 moredrug
Likely dose
XueZhiKang 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01686451
NCT01686451Phase 4Completed
CompareCT.gov

Comparison Between XueZhiKang and Simvastatin on Fatigue: a Single-center, Randomized Clinical Trial

Wenzhou Medical University·interventional·Posted Sep 18, 2012·Updated May 19, 2014

In Brief

A Phase 4 clinical trial evaluating XueZhiKang and simvastatin for Dyslipidemias. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Both XueZhiKang and Statins are cholesterol-lowering medications that are often prescribed for individuals with high cholesterol and who are at risk for cardiovascular disease (CVD). Several studies, including one randomized, double-blind, placebo-controlled clinical trial, have suggested that the use of statins is more frequently associated with fatigue. And XueZhiKang may be not. The purpose of this study is to compare the effect of these two medications on fatigue in persons who are at moderate to low CVD risk based on the risk estimation system in ESC(European Society of Cardiology)/ESA(European Atherosclerosis Society) guidelines (2011) for the management of dyslipidemias.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 18, 2012
Enrollment StartAug 1, 2012
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.8 years ago

Interventions

XueZhiKangdrug

Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.

simvastatindrug

Participants will receive 20mg of simvastatin daily for 4 weeks.